Microfluidic cell sorting - A new approach towards implantable artificial lungs

微流控细胞分选——植入式人工肺的新方法

• 批准号: 346973506
• 负责人: Professor Dr. Rolf Rossaint
• 金额: --
• 依托单位: Klinik für Anästhesiologie
• 依托单位国家: 德国
• 项目类别: Priority Programmes
• 财政年份: 2017
• 资助国家: 德国
• 起止时间: 2016-12-31 至 2020-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/346973506?language=en
• 关键词: Microfluidic; cell; sorting; new; approach

Extracorporeal lung assist (ECLA) is a life saving measure for patients suffering from acute pulmonary failure. Despite several improvements of recent ECLA devices (e.g. anticoagulant coatings, reduced shear stress, miniaturization), the technology is still prone to diverse complications. Thrombus formation on the membrane is still one of the most critical events. New concepts are needed to reach the next level in artificial lung assist (ALA) technology, aiming towards long term hemocompatible and implantable artificial lungs. Within the SPP 2014 this project targets the implementation of microfluidic cell sorting technology as a fundamental new strategy in ALA research. As a feasibility proof we developed a cell sorting device which already enables platelet separation of up to 73% from the remaining blood flow assigned for re-oxygenation. In this three staged project, we aim at the advancement of the first cell sorting device to a platelet-bypass for ALA systems which should reduce platelet contact to the oxygenator membrane, and enable reunification of the platelets with the re-oxygenated blood after the membrane lung passage (A). This should limit coagulation-, and inflammation activation, and finally thrombus formation on the membrane. The coagulation activating and gas transport properties of such a microfluidic-based ALA system will be assess in vitro (Mock Loop, B) and in vivo in a mouse ECLA model (C).

体外循环肺辅助（ECLA）是一种挽救急性肺功能衰竭患者生命的措施。尽管最近的ECLA设备（如抗凝剂涂层，降低剪切应力，小型化）的几个改进，该技术仍然是容易出现各种并发症。膜上血栓的形成仍然是最关键的事件之一。人工肺辅助（ALA）技术需要新的概念来达到下一个水平，旨在实现长期血液相容性和植入式人工肺。在SPP 2014中，该项目的目标是将微流控细胞分选技术作为ALA研究的一项基本新战略。作为可行性证明，我们开发了一种细胞分选装置，该装置已经能够从分配用于再氧合的剩余血流中分离高达73%的血小板。在这三个阶段的项目中，我们的目标是将第一个细胞分选装置改进为用于ALA系统的血小板旁路，这将减少血小板与氧合器膜的接触，并使血小板在膜肺通道后与再氧合血液重新结合（A）。这应该限制凝血和炎症激活，并最终限制膜上的血栓形成。将在体外（模拟环，B）和在小鼠ECLA模型（C）中体内评估这种基于微流体的ALA系统的凝血激活和气体转运性质。